James R. Klaiber, Pryor Cashman; Michael B. Kades, attorney, Federal Trade Comm; Steven J. Moore, Kelley Drye & Warren LLP
How can the ability of parties to settle an action for patent infringement be reconciled with the Federal Trade Commission’s focus on preventing what the commission terms “pay-for-delay” settlements of drug patent litigations? Why did the DOJ investigate the $4.5 billion sale of Nortel’s patent portfolio and other large technology patent deals? What is the effect of the Therasense decision on Walker Process claims? A panel of experts will tackle these and other issues during this lively moderated discussion.